AZD1480 (AZD-1480) is a selective, orally bioavailable and ATP-competitive inhibitor of JAK2 (Janus-associated kinase) with potential antitumor activity.

JAK3-IN-6 is a novel potent, selective, and irreversible inhibitor of Janus Associated Kinase 3 (JAK3) with anti-inflammatory effects.

Fedratinib (formerly SAR302503 or TG101348; brand name Inrebic) is a novel, potent, selective, orally bioavailable, small-molecule and ATP-competitive inhibitor of janus kinase 2 (JAK2) with an IC50 of 3 nM.

TCJL-37 is a potent TYK2 inhibitor.

FM 479 (FM479) is a negative control for FM-381 with no activity on JAK3 or other kinases.

Oclacitinib maleate (formerly PF-03394197 maleate) is a novel and potent inhibitor of JAK (Janus kinase) family members with IC50 values ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM.

S-Ruxolitinib, the S-enantiomer of ruxolitinib which is also known as INC424 and INCB18424 or INCB018424, is the first-in class, potent, selective, and orally bioavailable JAK1/2 (Janus-associated kinase) inhibitor with IC50 of 3.3 nM/2.8 nM in cell-free assays, it exhibits >130-fold selectivity for JAK1/2 versus JAK3.

Filgotinib (also known as GLPG0634; GLPG-0634; Jyseleca) is a novel, potent and selective JAK1 (Janus kinase) inhibitor with potential anti-inflammatory activity.

Pyridone 6 (also known as P6, CMP 6 or JAK Inhibitor I) is a pan-JAK (Janus-activated kinase) inhibitor with potential anti-AD and anticancer activity.

BMS-911543 (BMS911543) is a potent, selective and orally bioavailable inhibitor of JAK2 (Janus-associated kinase) with potential anticancer activity.